(Reuters) - The National Institute for Health and Clinical Excellence
said on Monday it was now recommending the 25,000 pounds-a-year drug, known generically as bortezomib, for the treatment of multiple myeloma, a type of blood cancer.
Read more at Reuters.com Government Filings News
said on Monday it was now recommending the 25,000 pounds-a-year drug, known generically as bortezomib, for the treatment of multiple myeloma, a type of blood cancer.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment